Interface Biologics Poster Presentation at AUA 2019, Chicago, IL
TORONTO, Canada, May 2, 2019 – Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, will be presenting a poster at the American Urological Association 2019 meeting (in collaboration with University of Western Ontario and Lawson Health Research Institute).

Details are as follows:

Title: In vitro evaluation of novel surface modifying molecules to prevent bacterial adhesion to urological devices (Poster number MP71-09)

Authors: Christopher Munday, Alexandra Piotrowicz, Kyle MacDonald, Antonio Cillero, Jeannette Ho, John Denstedt, Jeremy P. Burton

Date: Monday May 6th, 2019

Time: 7:00 am – 9:00 am

Location:  McCormick Place: MCP W179a

About Interface Biologics, Inc. Interface Biologics (IBI) is an early commercial stage privately held company that develops innovative materials for Medtech and Pharmaceutical applications. IBI surface modification additives are used in FDA-approved medical devices and are clinically proven to reduce infection and thrombus-related complications.  IBI’s sustained local drug delivery technology is applicable across a range of drug classes and medical specialties with an initial focus on ophthalmology.

About AUA: Founded in 1902, the AUA is a premier urologic association, providing invaluable support to the urologic community. Their mission is to promote the highest standards of urological clinical care through education, research and the formulation of health care policy. Learn more at For conference details visit

Media Contact: Julie Fotheringham, Partner, Hageman Communications M: 416-951-7988 E:

Powered by Innovasium